Skip to main content

Table 3 Proportion of patients with post-diagnosis health services utilization, stratified by alternative bone metastasis measures

From: Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer

   Claims Approach 3 SEER measure
Full M1 sample Concurrent BM No concurrent BM   BM at diagnosis No BM at diagnosis  
N = 2,708 N = 1,198 N = 1,510   N = 1,694 N = 1,014  
(44.2%) (55.8%) (62.6%) (37.4%)
 N   Col%  N   Col%  N   Col% P-value  N   Col%  N   Col% P-value
Post-diagnosis resource utilization (i.e., till end of follow-up)             
 Bone mineral density (BMD) 109 4.0 40 3.3 69 4.6 0.11 71 4.2 38 3.8 0.57
 Test
 PSA test 2,148 79.3 906 75.6 1,242 82.3 <0.01 1,389 82.0 759 74.9 <0.01
 Oncologist visit 1,681 62.1 857 71.5 824 54.6 <0.01 1,041 61.5 640 63.1 0.39
 Nuclear medicine specialist NR NR NR + NR - 0.07 NR >0 NR 0.0 0.01
 Visit
 Radiation oncologist visit 1,066 39.4 528 44.1 538 35.6 <0.01 687 40.6 379 37.4 0.10
 Bone biopsy 79 2.9 62 5.2 17 1.1 <0.01 47 2.8 32 3.2 0.57
 Bone or joint imaging 2,200 81.2 1,006 84.0 1,194 79.1 <0.01 1,406 83.0 794 78.3 <0.01
Treatment receipt (Part B)             
 Radiation 889 32.8 445 37.2 444 29.4 <0.01 581 34.3 308 30.4 0.04
 External Beam radiation 839 31.0 425 35.5 414 27.4 <0.01 553 32.6 286 28.2 0.02
 Therapy
 Radiopharmaceutical therapy 91 3.4 60 5.0 31 2.1 <0.01 72 4.3 19 1.9 <0.01
 Bisphosphonates IV 862 31.8 494 41.2 368 24.4 <0.01 593 35.0 269 26.5 <0.01
 Erythropoietin 535 19.8 274 22.9 261 17.3 <0.01 352 20.8 183 18.1 0.08
 Opioids (moderate-severe) 624 23.0 248 20.7 376 24.9 0.01 379 22.4 245 24.2 0.28
   Claims Approach 3 SEER measure
Full M1 sample Concurrent BM No concurrent BM   BM at diagnosis No BM at diagnosis  
N = 2,708 N = 1,198 N = 1,510   N = 1,694 N = 1,014  
(44.2%) (55.8%) (62.6%) (37.4%)
 N   Col%  N   Col%  N   Col% P-value  N   Col%  N   Col% P-value
Resource utilization during the 90-day diagnosis period             
 PSA test 1,629 60.2 698 58.3 931 61.7 0.07 1,046 61.8 583 57.5 0.03
 Bone biopsy 65 2.4 NR + NR - <0.01 42 2.5 23 2.3 0.73
 Bone or joint imaging 2,009 74.2 999 83.4 1,010 66.9 <0.01 1,317 77.7 692 68.2 <0.01
  Mean S.D. Mean S.D. Mean S.D. p-value Mean S.D. Mean S.D. p-value
Post-diagnosis resource utilization (i.e., till end of follow-up)             
 Number of BMD tests 0.04 0.21 0.03 0.19 0.05 0.22 0.09 0.04 0.22 0.04 0.19 0.39
 Number of PSA tests 8.16 10.01 8.26 10.77 8.08 9.38 0.63 8.81 10.41 7.07 9.21 <0.01
 Number of PSA tests among patients with PSA tests 10.29 10.23 10.93 11.15 9.82 9.47 0.02 10.75 10.56 9.44 9.54 <0.01
 Number of bone biopsies 0.03 0.18 0.05 0.24 0.01 0.11 <0.01 0.03 0.18 0.03 0.19 0.53
 Number of bone or joint imaging 1.65 1.58 1.67 1.56 1.64 1.61 0.60 1.73 1.61 1.52 1.53 <0.01
Resource utilization during the 90-day diagnosis period             
 Number of PSA tests 0.89 0.92 0.92 1.01 0.86 0.84 0.07 0.92 0.94 0.83 0.89 0.01
 Number of bone biopsies 0.02 0.16 0.05 0.23 0.003 0.06 <0.01 0.03 0.17 0.02 0.15 0.60
 Number of bone or joint imaging 0.76 0.47 0.86 0.42 0.68 0.49 <0.01 0.79 0.44 0.70 0.49 <0.01
  1. NR, Not reported due to small sample size, per data use agreement; ‘+’ means that the column% is greater than the percentage for the full sample while ‘-‘ means that the column% is smaller than the percentage for the full sample.